INVA
Innoviva, Inc.
Biotechnology · Healthcare · United States
21.31
close · 2026-10-29
value
89
cheaper than peers89
quality
84
stronger fundamentals84
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 9.64× | 86 |
| price to book | 1.26× | 83 |
| price to sales | 3.80× | 82 |
| EV to EBITDA | 6.90× | 66 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 50.7% | 95 |
| operating margin | 40.1% | 94 |
| debt to equity | 24.7% | 43 |
| revenue growth | 10.6% | 41 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $105.2M |
| employees | 159 |
| first trade | 2004-10-05 |
| next earnings | not reported |
| fundamentals updated | 2026-07-29 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 3.30 | 0.36 | 2.20 | 2.37 |
| free cash flow | $186.4M | $184.4M | $140.7M | $201.7M |
| net income | $271.2M | $23.4M | $179.7M | $213.9M |
| revenue | $411.3M | $358.7M | $310.5M | $331.3M |
| unusual items | $20.2M | -$59.2M | $11.1M | $254.5M |